Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EPS (Weighted Average and Diluted) (2016 - 2022)

RedHill Biopharma has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at $0.02 for Q2 2022.

  • Quarterly EPS (Weighted Average and Diluted) fell 66.67% to $0.02 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $0.19 through Jun 2022, up 179.17% year-over-year, with the annual reading at $0.01 for FY2023, 108.33% up from the prior year.
  • EPS (Weighted Average and Diluted) was $0.02 for Q2 2022 at RedHill Biopharma, down from $0.06 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.06 in Q2 2021 and troughed at $0.02 in Q2 2022.
  • The 3-year median for EPS (Weighted Average and Diluted) is $0.05 (2018), against an average of $0.04.
  • Year-over-year, EPS (Weighted Average and Diluted) decreased 16.67% in 2018 and then crashed 66.67% in 2022.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.05 in 2018, then grew by 20.0% to $0.06 in 2021, then crashed by 66.67% to $0.02 in 2022.
  • Per Business Quant, the three most recent readings for RDHL's EPS (Weighted Average and Diluted) are $0.02 (Q2 2022), $0.06 (Q2 2021), and $0.05 (Q2 2018).